Last 12 months
Inside the activity.
82 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 3 | 0 |
| Dec 2025 | 25 | 0 |
| Jan 2026 | 10 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 14 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 15 | 0 |
| Sep 2026 | 15 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 04, 2018 Filed May 1, 2018 15:25 UTC |
Danenberg NoamChief Operating Officer
|
GrantRestricted Stock Units (RSUs) | 40,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-18-005268 · f4040418danenberg_wizepharma.xml · nonDerivative · entry 1 Danenberg Noam · CIK 0001720898 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,515 F1 · kind: The RSUs were fully vested upon grant. F2 · price: The RSUs were granted as compensation for services as the COO of the Issuer. F3 · balance_after: Represents (i) 58,415 shares of the Issuer's Common Stock which are held by Mr. Danenberg through a company where Mr. Danenberg holds a minority interest and he does not serve as a director or an officer and (ii) 40,100 shares of Common Stock which were issued to N. Danenberg Holdings (2000) Ltd., a services company wholly owned by Mr. Danenberg ("Danenberg Holdings"), upon the vesting of RSUs that were granted by the Issuer on April 4, 2018. Read SEC document |
| April 04, 2018 Filed May 1, 2018 15:24 UTC |
Franck AmouyalDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001213900-18-005266 · f4040418amouyal_wizepharma.xml · derivative · entry 1 Franck Amouyal · CIK 0001723469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2025-04-04 F2 · price: The Stock Option was granted as compensation for services as a director of the Issuer. F1 · derivative.exercise_date: The Stock Option is exercisable in twelve equal installments over the three year period from the date of grant. Read SEC document |
| April 04, 2018 Filed Jun 4, 2018 21:06 UTC |
Belkin MichaelDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001213900-18-007201 · f4040418belkin_wizepharma.xml · derivative · entry 1 Belkin Michael · CIK 0001580801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2025-04-04 F2 · price: The Stock Option was granted as compensation for services as a director of the Issuer. F1 · derivative.exercise_date: The Stock Option is exercisable in twelve equal installments over the three year period from the date of grant. Read SEC document |
| March 26, 2018 Filed May 8, 2018 13:38 UTC |
Ridge Valley Corp10% owner
|
Conversion2017 Future Investment Rights · Derivative | 213,524 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001213900-18-005665 · f4032618ridgeval_wizepharm.xml · derivative · entry 2 Ridge Valley Corp · CIK 0001722230 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,853 Underlying: Common Stock · 13,524 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Ridge's outstanding loan to the Issuer in the principal amount of $274,048, which bears interest at an annual rate of 4% (the "Convertible Notes") is currently convertible (including accrued interest as of May 1, 2018), into 259,192 shares of common stock of the Issuer based on a loan conversion price per share of $1.1112. The maturity date of the Convertible Notes is December 31, 2018. Ridge has the right (the "2017 Investment Right") until June 30, 2019, to invest up to $126,344,658, at a price per share of $1.332. Read SEC document |
| March 26, 2018 Filed May 8, 2018 13:38 UTC |
Ridge Valley Corp10% owner
|
ConversionCommon Stock, par value $0.001 per share | 213,524 | $1.33 | $284,413.97 |
DisclosureSEC source: 0001213900-18-005665 · f4032618ridgeval_wizepharm.xml · nonDerivative · entry 1 Ridge Valley Corp · CIK 0001722230 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,394,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The 213,524 shares of common stock of the Issuer were issued upon the exercise of a portion of the 2017 Investment Rights (as defined below). F2 · balance_after: Represents (i) 1,040,760 shares of common stock of the Issuer, (ii) 259,192 shares of common stock of the Issuer issuable upon the conversion of the Convertible Notes (as defined below) and (iii) 94,853 shares of common stock issuable upon the exercise of the 2017 Investment Rights (as defined below). Ridge Valley Corporation ("Ridge") is a Seychelles corporation. Priscilla Julie is the sole director of Ridge and holds the voting and dispositive power of the shares of common stock beneficially owned by Ridge. Noam Danenberg, the Issuer's Chief Operating Officer, is also the son-in-law of Mrs. Hanna Harpaz, who owns 49% of Ridge. Read SEC document |
| March 26, 2018 Filed May 8, 2018 17:39 UTC |
Sadan Simcha10% owner
|
OtherWarrants · Derivative | 144,168 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001213900-18-005667 · f4032618sadan_wizepharma.xml · derivative · entry 2 Sadan Simcha · CIK 0001721347 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,869 Underlying: Common Stock · 144,168 shares Expires 2020-11-16 Read SEC document |
| March 26, 2018 Filed May 8, 2018 17:39 UTC |
Sadan Simcha10% owner
|
OtherCommon Stock, par value $0.001 per share | 144,168 | $1.97 | $284,414.63 |
DisclosureSEC source: 0001213900-18-005667 · f4032618sadan_wizepharma.xml · nonDerivative · entry 1 Sadan Simcha · CIK 0001721347 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 682,843 F1 · shares: The 144,168 shares of common stock of the Issuer were issued upon the exercise of a portion of warrants held by the reporting person. F2 · balance_after: Represents (i) 567,974 shares of common stock of the Issuer and (ii) 114,869 shares of common stock of the Issuer issuable upon the exercise of warrants. Read SEC document |
| March 26, 2018 Filed May 9, 2018 18:18 UTC |
Rimon Gold Assets Ltd10% owner
|
Conversion2016 Future Investment Rights · Derivative | 217,442 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001213900-18-005786 · f4032618rimon_wizepharma.xml · derivative · entry 2 Rimon Gold Assets Ltd · CIK 0001721808 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 392,055 Underlying: Common Stock · 217,442 shares Expires 2019-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Reporting Person's outstanding loan in the principal amount of $531,067, which bears interest at an annual rate of 4% (the "2016 Convertible Notes"), is convertible (including accrued interest), into 593,925 shares of common stock based on a conversion price per share of $0.9768. Reporting Person has the right, until June 30, 2019, to invest up to $796,601, in the aggregate, at an agreed price per share of $1.308 (the "2016 Investment Right"). Reporting Person 's outstanding loan to the Issuer in the principal amount of $274,048, which bears interest at an annual rate of 4% (the "2017 Convertible Notes") is currently convertible (including accrued interest), into 259,003 shares of common stock based on a loan conversion price per share of $1.1112. The maturity date of the 2016 Convertible Notes and the 2017 Convertible Notes is December 31, 2018. Reporting Person has the right (the "2017 Investment Right") until June 30, 2019, to invest up to $512,187, at a price per share of $1.332. Read SEC document |
| March 26, 2018 Filed May 9, 2018 18:18 UTC |
Rimon Gold Assets Ltd10% owner
|
ConversionCommon Stock, par value $0.001 per share | 217,442 | $1.31 | $284,414.14 |
DisclosureSEC source: 0001213900-18-005786 · f4032618rimon_wizepharma.xml · nonDerivative · entry 1 Rimon Gold Assets Ltd · CIK 0001721808 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,770,802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The 217,442 shares of common stock of the Issuer were issued upon the exercise of a portion of the 2016 Investment Rights (as defined below). F2 · balance_after: Represents (i) 217,442 shares of common stock, (ii) 593,925 shares of common stock issuable upon the conversion of the 2016 Convertible Notes (as defined below), (iii) 259,003 shares of common stock issuable upon the conversion of the 2017 Convertible Notes (as defined below), (iv) 392,055 shares of common stock issuable upon the exercise of Reporting Person's 2016 Investment Right (as defined below) and (v) 308,377 shares of common stock issuable upon the exercise of Reporting Person's 2017 Investment Right (as defined below). Reporting Person is an Israeli private company wholly owned by the Goldfinger Trust (the "Trust"), whose trustee is Abir Raveh (the "Trustee") and whose beneficiary is Yair Goldfinger. The Trust directs the management of Reporting Person, its investment and voting decisions and the Trustee directs the management of the Trust, its investment and voting decisions. Read SEC document |
| January 18, 2018 Filed Jan 22, 2018 21:18 UTC |
Zarachia Yaakov10% owner
|
PurchaseCommon Stock, par value $0.001 per share | 5,000 | $0.12 | $600.00 |
DisclosureSEC source: 0001213900-18-000756 · f4012218zarachia_wize.xml · nonDerivative · entry 1 Zarachia Yaakov · CIK 0001721667 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,371,892 Read SEC document |
| January 17, 2018 Filed Jan 19, 2018 22:08 UTC |
Zarachia Yaakov10% owner
|
PurchaseCommon Stock, par value $0.001 per share | 10,000 | $0.15 | $1,450.00 |
DisclosureSEC source: 0001213900-18-000721 · f4011618zarachia_wizepharma.xml · nonDerivative · entry 2 Zarachia Yaakov · CIK 0001721667 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,366,892 Read SEC document |
| January 16, 2018 Filed Jan 19, 2018 22:08 UTC |
Zarachia Yaakov10% owner
|
PurchaseCommon Stock, par value $0.001 per share | 13,000 | $0.15 | $1,943.50 |
DisclosureSEC source: 0001213900-18-000721 · f4011618zarachia_wizepharma.xml · nonDerivative · entry 1 Zarachia Yaakov · CIK 0001721667 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,356,892 Read SEC document |
| January 10, 2018 Filed Jan 16, 2018 11:08 UTC |
Zarachia Yaakov10% owner
|
PurchaseCommon Stock, par value $0.001 per share | 9,281 | $0.14 | $1,317.90 |
DisclosureSEC source: 0001213900-18-000508 · f4010918zarachia_wize.xml · nonDerivative · entry 3 Zarachia Yaakov · CIK 0001721667 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,343,892 Read SEC document |
| January 10, 2018 Filed Jan 16, 2018 11:08 UTC |
Zarachia Yaakov10% owner
|
PurchaseCommon Stock, par value $0.001 per share | 4,000 | $0.15 | $600.00 |
DisclosureSEC source: 0001213900-18-000508 · f4010918zarachia_wize.xml · nonDerivative · entry 2 Zarachia Yaakov · CIK 0001721667 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,334,674 Read SEC document |
| January 09, 2018 Filed Jan 16, 2018 11:08 UTC |
Zarachia Yaakov10% owner
|
PurchaseCommon Stock, par value $0.001 per share | 9,841 | $0.11 | $1,033.31 |
DisclosureSEC source: 0001213900-18-000508 · f4010918zarachia_wize.xml · nonDerivative · entry 1 Zarachia Yaakov · CIK 0001721667 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,330,674 Read SEC document |
| January 03, 2018 Filed Jan 8, 2018 12:17 UTC |
Zarachia Yaakov10% owner
|
PurchaseCommon Stock, par value $0.001 per share | 7,507 | $0.09 | $638.10 |
DisclosureSEC source: 0001213900-18-000218 · f4010318zarachia_wizepharma.xml · nonDerivative · entry 1 Zarachia Yaakov · CIK 0001721667 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,320,833 Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 11:34 UTC |
Zarachia Yaakov10% owner
|
PurchaseCommon Stock, par value $0.001 per share | 20,711 | $0.11 | $2,278.21 |
DisclosureSEC source: 0001213900-18-000008 · f4122817zarachia_wizepharma.xml · nonDerivative · entry 2 Zarachia Yaakov · CIK 0001721667 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,313,326 Read SEC document |
| December 28, 2017 Filed Jan 2, 2018 11:34 UTC |
Zarachia Yaakov10% owner
|
PurchaseCommon Stock, par value $0.001 per share | 9,289 | $0.11 | $1,021.79 |
DisclosureSEC source: 0001213900-18-000008 · f4122817zarachia_wizepharma.xml · nonDerivative · entry 1 Zarachia Yaakov · CIK 0001721667 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,292,615 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.